Allos is committed to expanding its product candidate portfolio and welcomes licensing and collaboration opportunities. Priority is given to differentiated technologies that have the potential to improve current standards of care or establish new points of therapeutic intervention. In order to best leverage our internal development expertise, we limit our search for licensing opportunities to small molecules or protein-based compounds that are currently undergoing clinical investigation or have established in vivo proof of efficacy.